American Century Companies Inc. Grows Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

American Century Companies Inc. grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 14.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 527,594 shares of the company’s stock after purchasing an additional 65,870 shares during the period. American Century Companies Inc. owned approximately 0.48% of Vaxcyte worth $39,839,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Darwin Global Management Ltd. increased its position in shares of Vaxcyte by 374.3% during the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after acquiring an additional 2,170,845 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after acquiring an additional 1,284,883 shares in the last quarter. Norges Bank bought a new stake in shares of Vaxcyte during the fourth quarter valued at approximately $57,494,000. Capital Research Global Investors increased its position in shares of Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after acquiring an additional 700,414 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Vaxcyte by 9.9% during the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after acquiring an additional 692,492 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Price Performance

Shares of PCVX stock opened at $116.75 on Wednesday. Vaxcyte, Inc. has a 1 year low of $44.20 and a 1 year high of $119.50. The firm has a fifty day moving average price of $87.05 and a 200-day moving average price of $75.47. The company has a market cap of $13.03 billion, a price-to-earnings ratio of -27.28 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter in the prior year, the company posted ($0.70) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Insider Activity

In other news, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the completion of the sale, the senior vice president now owns 30,826 shares of the company’s stock, valued at approximately $2,354,181.62. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, COO Jim Wassil sold 3,000 shares of Vaxcyte stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.34, for a total transaction of $229,020.00. Following the transaction, the chief operating officer now owns 210,503 shares in the company, valued at approximately $16,069,799.02. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Mikhail Eydelman sold 1,667 shares of Vaxcyte stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the transaction, the senior vice president now owns 30,826 shares in the company, valued at approximately $2,354,181.62. The disclosure for this sale can be found here. Insiders sold a total of 85,283 shares of company stock valued at $7,271,218 in the last 90 days. Company insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the subject of several analyst reports. Leerink Partners raised their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Needham & Company LLC raised their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Mizuho lifted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.